Presage, Celgene ally to identify new drug combos for solid tumor

Presage Biosciences and Celgene entered into a research alliance to find new drug combinations for solid tumors. Presage will get $5 million upfront, $8 million in equity investment plus potential future payments.

View Full Article in:

American City Business Journals · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX